Cryolife Stock Downgraded (CRY)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Cryolife (NYSE: CRY) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and disappointing return on equity.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 3.8%. Since the same quarter one year prior, revenues rose by 12.7%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • CRY has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.35, which illustrates the ability to avoid short-term cash problems.
  • The gross profit margin for CRYOLIFE INC is rather high; currently it is at 68.10%. Regardless of CRY's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, CRY's net profit margin of 4.60% is significantly lower than the same period one year prior.
  • The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Health Care Equipment & Supplies industry average. The net income has decreased by 23.8% when compared to the same quarter one year ago, dropping from $2.02 million to $1.54 million.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. In comparison to the other companies in the Health Care Equipment & Supplies industry and the overall market, CRYOLIFE INC's return on equity is significantly below that of the industry average and is below that of the S&P 500.
.

CryoLife, Inc. preserves and distributes human tissues for transplantation in the United States and internationally. The company also develops, manufactures, and commercializes medical devices for cardiac and vascular applications. The company has a P/E ratio of 20.3, above the S&P 500 P/E ratio of 17.7. Cryolife has a market cap of $155.9 million and is part of the health care sector and health services industry. Shares are up 20.8% year to date as of the close of trading on Tuesday.

You can view the full Cryolife Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.

null

More from Markets

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

Stocks Rise, Facebook Ignites a Nasdaq Rally

Stocks Rise, Facebook Ignites a Nasdaq Rally

Short Seller Chanos Slams Tesla's Musk, Accuses Him of 'Incinerating' Capital

Short Seller Chanos Slams Tesla's Musk, Accuses Him of 'Incinerating' Capital

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts